Breast Cancer Awareness Month: From Genetic Risk to Precision Health
Understanding the Genetic Dimension of Breast Cancer
Breast Cancer Awareness Month is an important opportunity to raise awareness about prevention, screening, early detection, and the factors that influence breast cancer risk.
While most breast cancers are not hereditary, genetic factors can play an important role in cancer susceptibility for some individuals. Understanding the genetic component of breast cancer can provide valuable information for risk assessment, screening, family evaluation, and personalized healthcare [1,2].
Among the best-known genes associated with hereditary breast cancer are BRCA1 and BRCA2. These tumor suppressor genes are involved in repairing DNA damage through the homologous recombination repair (HRR) pathway. Certain inherited pathogenic variants in these genes can increase the risk of breast, ovarian, pancreatic, prostate, and other cancers [2,3].
However, hereditary cancer risk extends beyond BRCA1 and BRCA2. Other genes, including PALB2, TP53, PTEN, CDH1, STK11, ATM, and CHEK2, may also be associated with increased susceptibility to breast cancer and other malignancies [1,4].
Understanding this broader genetic landscape is becoming increasingly important in modern cancer risk assessment.
When Family History Raises a Question
Family history remains an important starting point when assessing hereditary cancer risk.
Certain patterns may suggest the possibility of an inherited predisposition, including:
- Breast cancer diagnosed at a younger age
- Multiple relatives with breast cancer
- Breast cancer affecting both breasts or multiple primary breast cancers
- Male breast cancer
- A family history of ovarian, pancreatic, or certain prostate cancers
- A known hereditary cancer-associated variant in the family
However, hereditary risk is not always visible in a family tree. Small families, limited knowledge of relatives' medical histories, adoption, and other factors can make inherited patterns difficult to recognize.
For this reason, the absence of a strong family history does not necessarily exclude hereditary cancer risk [1,2]. Genetic testing can provide an additional layer of information by directly assessing germline genetic variation.
What Can Hereditary Cancer Genetic Testing Tell Us?
Hereditary cancer testing analyzes germline DNA, typically from a blood or saliva sample, to identify genetic variants associated with inherited cancer susceptibility.
Modern testing can evaluate multiple cancer-associated genes simultaneously through multigene panel testing. This approach can provide a broader assessment of hereditary cancer risk than testing a single gene alone [1,4].
Depending on the individual’s personal and family history and the genes included in the test, genetic testing may help:
- Identify pathogenic or likely pathogenic inherited variants
- Provide additional information about cancer susceptibility
- Support personalized screening and risk-management discussions
- Identify relatives who may benefit from genetic evaluation
- Support cascade testing within families
- Contribute to genetic counseling and clinical decision-making
Genetic testing is not a standalone assessment. Its value comes from interpreting genomic findings alongside personal history, family history, clinical information, and appropriate professional guidance.
Understanding Genetic Test Results
Genetic testing results should be interpreted within the context of the individual’s personal and family history. Results may identify a pathogenic or likely pathogenic variant associated with increased cancer susceptibility, while a negative result does not necessarily exclude hereditary risk.
A variant of uncertain significance (VUS) indicates that current evidence is insufficient to determine its clinical relevance and should not independently guide clinical management.
This distinction is essential in genomic medicine, where the interpretation of genetic information is as important as the identification of the variant itself.
From Individual Risk to Family Risk
One of the unique aspects of hereditary cancer genetics is that a clinically significant finding may have implications beyond the individual tested.
When a pathogenic or likely pathogenic inherited variant is identified, biological relatives may have the opportunity to discuss targeted testing with a healthcare professional or genetic counselor.
This approach is known as cascade testing and can help determine whether the same inherited variant may be present in other family members [5].
In this way, genetic information can become an important part of family health assessment and potentially help guide appropriate risk management across generations.
Genetics as Part of Precision Health
Genetic information represents one component of a broader precision-health approach.
- A meaningful assessment of cancer risk may integrate:
- Personal cancer history
- Family history
- Genetic findings
- Clinical characteristics
- Screening and imaging information
- Other established risk factors
The goal is not simply to identify genetic variants, but to translate genomic information into clinically meaningful insight. As genomic technologies continue to advance, hereditary cancer testing is becoming an increasingly important component of personalized risk assessment and preventive healthcare.
DNA GTx: Advancing Genomic Insight in Hereditary Cancer
At DNA GTx, we recognize the growing role of genomic information in the evolution of personalized healthcare.
Our hereditary cancer testing solutions are designed to investigate BRCA1, BRCA2, and other clinically relevant cancer-associated genes, according to the selected panel and clinical indication.
Through next-generation sequencing, bioinformatic analysis, and genomic interpretation, DNA GTx supports healthcare professionals in evaluating inherited cancer susceptibility and generating clinically meaningful genomic information.
- Our approach supports:
- Comprehensive hereditary cancer gene analysis
- Identification of clinically relevant inherited variants
- Genomic assessment of hereditary cancer susceptibility
- Family risk evaluation and cascade testing
- Integration of genomic information into precision-health strategies
At DNA GTx, we are committed to connecting advanced genomic technology with meaningful clinical insight, supporting a future in which genetic information can contribute to more informed healthcare decisions.
This Breast Cancer Awareness Month
Breast Cancer Awareness Month is more than a reminder about screening and early detection. It is also an opportunity to recognize the increasingly important role of genetics in understanding cancer susceptibility.
For individuals with relevant personal or family histories, hereditary cancer testing may provide additional information to support risk assessment and clinical decision-making. For families, identifying an inherited genetic variant can open the door to more informed evaluation across generations.
Know Your Risk. Understand Your Genes. Make Informed Decisions.
DNA GTx — Advancing Genomics for Precision Health
Genetic testing should be considered and interpreted in the context of personal and family history and appropriate professional clinical or genetic counseling. Genetic testing does not determine with certainty whether an individual will develop cancer.
📚 References
- National Cancer Institute. Genetic Testing for Inherited Cancer Risk: Genetic Testing Fact Sheet.
- National Cancer Institute. BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet.
- National Cancer Institute. Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version.
- American Cancer Society. Genetic Counseling and Testing for Breast Cancer Risk.
- National Cancer Institute. Cascade Genetic Testing.
Recent Blogs
Vous avez une question ?
Vous avez une question ou une demande spécifique ? Remplissez le formulaire ci dessous et notre équipe vous répondra dans les plus brefs délais.
